Promoter Hypermethylation‐Induced Silencing of FXYD1 Drives Breast Cancer Metastasis via DDX5‐Mediated Wnt/β‐Catenin Pathway Activation
Advanced Science · 2026-05 · 13 (27)
DOI: 10.1002/advs.202521921 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 04.03.2026. Verfasst von Ping Wen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Chongqing University Cancer Hospital, School of Medicine, Chongqing University, Chongqing, China. Hauptthemen laut MEDLINE: DEAD-box RNA Helicases, DNA Methylation, Breast Neoplasms, Wnt Signaling Pathway. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing, Chongqing Science and Health Joint Medical Research Project.
Abstract (Originalsprache)
Epigenetic silencing of tumor suppressor genes is a hallmark of cancer progression. The FXYD (FXYD domain‐containing ion transport regulator) family, classically known for ion transport regulation, has recently been implicated in oncogenesis; however, the role of its founding member, FXYD1, in breast cancer remains unclear. Here, FXYD1 is identified as a significantly downregulated gene in breast cancer tissues, and low FXYD1 expression is associated with unfavorable patient prognosis. Integrative transcriptomic, clinical, and epigenetic analyses revealed that promoter hypermethylation drives FXYD1 silencing. Functional restoration of FXYD1 suppressed cell proliferation, migration, and lung metastasis both in vitro and in vivo. Mechanistically, FXYD1 acts as a nuclear scaffold that recruits the E3 ubiquitin ligase MAEA to the RNA helicase DDX5, a coactivator of β‐catenin, promoting K63‐linked ubiquitination and proteasomal degradation of DDX5. This process reduces β‐catenin stability, impairs its nuclear translocation, and attenuates Wnt target gene expression. Collectively, our findings uncover a previously unrecognized FXYD1–MAEA–DDX5 axis that inhibits Wnt/β‐catenin signaling through a non‐canonical ubiquitin–proteasome pathway, establishing FXYD1 as a tumor suppressor and potential prognostic biomarker and therapeutic target in breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chongqing University Cancer Hospital, School of Medicine, Chongqing University, Chongqing, China.
- Department of Breast Cancer Center, Chongqing University Cancer Hospital, Chongqing, China.
- Radiation Oncology Center, Chongqing University Cancer Hospital, Chongqing, China.
- Chongqing Key Laboratory for Intelligent Oncology in Breast Cancer (iCQBC), Chongqing University Cancer Hospital, Chongqing, China.
ORCID-Profile: Xiaohua Zeng
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
- Chongqing Science and Health Joint Medical Research Project
- Chongqing Medical Youth Top Talent Program
- Science and Technology Research Program of Chongqing Municipal Education Commission
- Special Key Projects of Technological Innovation and Application Development in Chongqing
- Natural Science Foundation of Chongqing Municipality
Zitieren
APA
Wen, P., Qu, F., Wang, L., Shao, Q., Li, S., Qin, Y., Jiang, D., Zhang, S., Sui, J., Wang, G., Zhang, N., & Zeng, X. (2026). Promoter Hypermethylation‐Induced Silencing of FXYD1 Drives Breast Cancer Metastasis via DDX5‐Mediated Wnt/β‐Catenin Pathway Activation. Advanced Science, 13(27). https://doi.org/10.1002/advs.202521921
Vancouver
Wen P, Qu F, Wang L, Shao Q, Li S, Qin Y, et al. Promoter Hypermethylation‐Induced Silencing of FXYD1 Drives Breast Cancer Metastasis via DDX5‐Mediated Wnt/β‐Catenin Pathway Activation. Advanced Science. 2026;13(27). doi:10.1002/advs.202521921
BibTeX
@article{Wen2026,
author = {Wen, Ping and Qu, Fanli and Wang, Long and Shao, Qing and Li, Sisi and Qin, Yang and Jiang, Dongping and Zhang, Senmiao and Sui, Jiangdong and Wang, Guanwen and Zhang, Ningning and Zeng, Xiaohua},
title = {Promoter Hypermethylation‐Induced Silencing of FXYD1 Drives Breast Cancer Metastasis via DDX5‐Mediated Wnt/β‐Catenin Pathway Activation},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {27},
doi = {10.1002/advs.202521921}
}
EUVIMED